Induced Pluripotent Stem Cell Vaccine Promising for CancerLast Updated: February 15, 2018. Induced pluripotent stem cell vaccines prevent tumor growth in syngeneic murine cancer models in a prophylactic setting, according to a study published online Feb. 15 in Cell Stem Cell.
THURSDAY, Feb. 15, 2018 (HealthDay News) -- Induced pluripotent stem cell (iPSC) vaccines prevent tumor growth in syngeneic murine cancer models in a prophylactic setting, according to a study published online Feb. 15 in Cell Stem Cell.
Noting that it may be possible for iPSCs to be harnessed to elicit anti-tumor responses in cancer vaccines, Nigel G. Kooreman, M.D., from the Stanford University School of Medicine in California, and colleagues conducted a proof-of-principle study for using irradiated iPSCs in autologous anti-tumor vaccines.
The researchers found that iPSC vaccines prevented tumor growth in syngeneic murine breast cancer, mesothelioma, and melanoma models in a prophylactic setting. The iPSC vaccine inhibited melanoma recurrence at the resection site as an adjuvant and reduced metastatic tumor load, which was correlated with fewer Th17 cells and increased CD11b+GR1hi myeloid cells. Adoptive transfer of T cells isolated from tumor-bearing mice treated with the vaccine inhibited growth of tumors in unvaccinated recipients.
"Our data suggest a generalizable strategy for multiple types of cancer that could prove highly valuable in clinical immunotherapy," the authors write.
|Previous: Patient Involvement May Promote Hand Washing in the Hospital||Next: Patients Want Physicians to Have Greater Connectivity|
Reader comments on this article are listed below. Review our comments policy.